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Significance of the Study
• In this study, the effect of metabolic syndrome on health-related quality of life (HRQOL) was examined 
in patients with suspected nonalcoholic steatohepatitis. A significant association between metabolic 
syndrome and HRQOL was observed in these patients. This finding could be useful in therapy and in 
devising health policy.
DOI: 10.1159/000487397
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Abstract
Objective: This study was designed to examine the effect of 
metabolic syndrome (MetS) on health-related quality of life 
(HRQOL) in patients with suspected nonalcoholic steatohep-
atitis (NASH). Subjects and Methods: Three hundred thirty-
two patients (236 males and 96 females) with suspected 
NASH from the Amol cohort study were included in this study. 
MetS was diagnosed based on Adult Treatment Panel III crite-
ria and HRQOL was measured using the 12-Item Short-Form 
Health Survey (SF-12) questionnaire (with 8 subscales and 2 
summary components). A multivariable linear regression 
model was used to assess the independent effect of MetS on 
HRQOL. Results: The mean age of the study population was 
42 ± 13 years (range 18–82). The prevalence of MetS was 
43.4% (n = 144) and the mean scores on the Physical Compo-
nent Summary (PCS) and the Mental Component Summary 
were 72.4 ± 20.86 and 42.7 ± 12.42, respectively. The multi-
variable linear regression model showed that MetS was nega-
tively associated with 4 subscales of HRQOL that included: 
role limitations due to physical problems (RP) (B = –14.05, p = 
0.004), bodily pain (BP) (B = –7.37, p = 0.02), vitality (VT) (B = 
–7.72, p = 0.022), and role limitations due to emotional prob-
lems (RE) (B = –12.67, p = 0.005) after adjustment for other 
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variables. Also, MetS had a borderline association with the 
general health and mental health subscales and the PCS (p < 
0.1). Conclusion: In this study, there was a strong association 
between MetS and 4 subscales (RP, BP, VT, and RE) of HRQOL 
in patients with suspected NASH; this could be considered as 
a part of health policy to improve general health.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
With the increasing trend toward overweight and obe-
sity in developing countries [1], health policy-makers are 
progressively faced with the problems and dilemmas re-
lated to nonalcoholic fatty liver disease (NAFLD) [2]. The 
spectrum of this disease ranges from simple steatosis to 
cirrhosis and eventually hepatocellular carcinoma. Cur-
rently NAFLD is considered the most prevalent chronic 
liver disease in many countries including Iran [3]. NAFLD 
is a complex metabolic condition in which both lifestyle 
and genetic factors have a pathogenic role and it has been 
increasingly recognized as a major cause of liver-related 
morbidity and mortality [4, 5]. In this setting, nonalco-
holic steatohepatitis (NASH) is histologically determined 
by hepatic steatosis and cellular damage with features of 
inflammation and/or fibrosis [6, 7]. NASH may progress 
to liver fibrosis or cirrhosis and it is likely that this disease 
could become the most common cause of liver-related 
mortality in the near future [8]. The pathogenesis of 
NAFLD/NASH is not clear, and many hypotheses had 
been proposed. Obesity, diabetes mellitus, and dyslipid-
emia have been reported as predisposing risk factors for 
NASH [7]. Due to the variety in the pathogenesis of 
NAFLD, its clinical presentation may be different. Many 
patients with NAFLD/NASH are asymptomatic [9]. Some 
comorbidities such as metabolic syndrome (MetS) and 
obesity might occur in NAFLD/NASH patients [10], but 
MetS is a common comorbidity in subjects with NAFLD/
NASH and could affect their health-related quality of life 
(HRQOL). There have been only a few studies (especial- 
ly in our region) assessing the link between MetS and 
HRQOL in NAFLD/NASH patients [11, 12]. Most stud-
ies have evaluated MetS status and QOL in NAFLD/
NASH patients separately. Also, considering the social 
and economic burden of NAFLD/NASH, it is estimated 
that knowing the HRQOL and associated factors (espe-
cially MetS) of patients could be of great importance in 
health policy-making as well as in therapy. 
The hypothesis of this study was that HRQOL scores 
in suspected NASH patients would be associated with 
MetS. Thus, the aim was to evaluate the effects of MetS on 
HRQOL, and to investigate whether or not the demo-
graphics and clinical data including sex, age, marital sta-
tus, occupational status, exercise status, BMI, history of 
smoking, history of drug abuse, history of alcohol con-
sumption, history of diabetes, and hypertension would 
moderate this relationship.
Subjects and Methods
Design and Sample
This cross-sectional study was conducted within the frame-
work of Amol cohort health study (phase 1; 2008–2011). In this 
cohort, a total of 7,104 subjects aged 10–90 years were selected by 
cluster random sampling from Amol healthcare centers. Nine 
hundred sixty persons at baseline were excluded due to unwilling-
ness to participate, moving, or pregnancy. Thus, this study was 
conducted in 6,140 participants. All of them underwent a complete 
physical examination and fasting blood samples were obtained for 
assessment of fasting blood sugar and the lipid profile. A transab-
dominal ultrasonography was performed on each participant. Ul-
trasonography was performed by a senior radiologist using previ-
ously published methods [5]. Subjects with any signs or symptoms 
of liver diseases were referred for more specific evaluations.
Definition of Suspected NASH
Liver biopsy remains the gold standard for diagnosis of the degree 
of hepatosteatosis and inflammatory activity and NASH [13]. Also a 
previous study revealed that age, glucose level, diastolic blood pres-
sure, systolic blood pressure, BMI, and lipid profile are associated 
with the diagnosis of NAFLD [14]. Because liver biopsy is an invasive 
technique it was not done in the present study, but patients with 
fatty liver on transabdominal ultrasonography along with an elevated 
serum level of alanine aminotransferase without any other liver dis-
eases were considered “suspected” NASH patients. 
Definition of MetS
MetS was defined based on fulfillment of at least 3 of the 5 com-
ponents of the National Cholesterol Education Program Adult 
Treatment Panel III criteria as follows [15]: waist circumference > 
102 cm (40 in) for males and > 88 cm (35 in) for females, blood 
pressure ≥130/≥85 mm Hg, fasting glucose ≥100 mg/dL, triglyc-
erides ≥150 mg/dL, and HDL cholesterol < 40 mg/dL for males and 
< 50 mg/dL for females. 
Study Population
Patients were selected based on our definition of suspected 
NASH. Exclusion criteria were: (1) age < 18 years, (2) having other 
known liver diseases, and (3) unwillingness to participate in this 
study. The research was explained to all of the participants and 
written consent was obtained from each one.
Three hundred thirty-nine subjects with suspected NASH were 
detected from all of the participants (6,140 persons). Seven ques-
tionnaires had more than 20% missing data and thus were exclud-
ed from this study. Therefore, 332 subjects with suspected NASH 
who had complete sociodemographic, clinical, and HRQOL data 
were recruited for data analysis. 
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Data Collection
Twelve-Item Short-Form Questionnaire
The 12-Item Short-Form Questionnaire (SF-12) is a multidi-
mensional questionnaire on HRQOL. This questionnaire had been 
previously developed and tested among the general Iranian popu-
lation [16]. The SF-12 contains a Likert scale format including 12 
items and 8 HRQOL subscales derived from aggregated items. The 
SF-12 subscales were: (1) physical functioning (2 items), (2) role 
limitations due to physical problems (RP) (2 items), (3) bodily pain 
(BP) (1 item), (4) general health (1 item), (5) vitality (VT) (1 item), 
(6) social functioning (SF) (1 item), (7) role limitations due to 
emotional problems (RE) (2 items), and (8) mental health (MH) 
(2 items). In summary, subscales 1–4 covered the Physical Com-
ponent Summary (PCS) and subscales 5–8 covered the Mental 
Component Summary (MCS). The items were computed based on 
scores of 0–100, where 0 indicated the lowest level of health mea-
sured and 100 indicated the highest level of health measured [17]. 
Eight subscales and 2 summary components of the SF-12 question-
naire were considered as dependent variables.
Sociodemographic and Clinical Factors Questionnaire (except 
MetS and Its Components) 
Demographic and clinical data included gender (male or fe-
male), age (≤42 years or > 42 years), marital status (married or 
single), occupational status (retired or active), exercise status (hav-
ing daily regular physical activity; yes or no), obesity (yes or no), 
history of smoking (yes or no), history of drug abuse (yes or no), 
history of alcohol consumption (yes or no), history of diabetes (yes 
or no), and history of hypertension (yes or no) and were consid-
ered covariates in this study.
Statistical Analysis
Statistical evaluations were performed using IBM SPSS Statistics 
for Windows (SPSS), version 20.0 (IBM Corp., Armonk, NY, USA). 
A descriptive analysis (frequencies, percentages, ranges, means, and 
SD) of the sociodemographic and clinical factors is reported. The 
Kolmogorov-Smirnov test was used to assess the normality of the 
data. The Pearson correlation coefficient was used to determine the 
level of agreement between the 8 subscales of the SF-12. The uni-
variate test (t independent) was used to investigate the association 
between subjects’ HRQOL and independent and covariate variables 
in the first step. Multivariable linear regression models (with the 
backward method) were used to assess the independent effect of 
MetS on HRQOL. Transformed scores were used for statistical anal-
yses in all subscales. p < 0.2 in univariate analyses and p < 0.05 in 
multivariable analyses were considered statistically significant.
Results
Demographic and other pertinent data are shown in 
Table 1. The mean age of the study population was 42 ± 
13 years (range 18–82), the mean BMI was 31.5± 4.7, and 
144 (43.4%) subjects had MetS. 
Among the different subscales of the SF-12, the lowest 
and highest mean scores were observed in SF subscale 
(mean: 20.9 ± 25.6) and the BP subscale (mean: 77.8 ± 27.9), 
Table 1. Characteristics of the study population
Characteristic Patients, n (%)
Sex
Male 236 (71.1)
Female 96 (28.9)
Age
<42 years 162 (48.8)
≥42 years 170 (51.2)
Education level
Diploma (academic) 176 (53)
No diploma 156 (47)
Marital status
Married 288 (86.7)
Single 44 (13.3)
Occupational status1
Active 136 (43.5)
Retired 177 (56.5)
Obesity
No 15 (4.5)
Yes 317 (95.5)
Exercise status
No 249 (75)
Yes 83 (25)
History of smoking
No 280 (84.3)
Yes 52 (15.7)
Passive smoker
No 226 (68.1)
Yes 106 (31.9)
History of drug abuse
No 205 (61.7)
Yes 127 (38.3)
History of alcohol drinking
No 296 (89.2)
Yes 36 (10.8)
History of diabetes
No 293 (88.3)
Yes 39 (11.7)
History of hypertension
No 235 (70.8)
Yes 97 (29.2)
Metabolic syndrome
No 188 (56.6)
Yes 144 (43.4)
There were 332 patients in total. 1 Some missing data exist for 
this variable.
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respectively. Also, the mean scores on the PCS and MCS 
were 72.4 ± 20.86 and 42.7 ± 12.42, respectively (Fig. 1). 
The correlations between the 8 subscales of the SF-12 
are presented in Table 2; as can be observed, there were 
statistically significant correlations between all of the sub-
scales. There were also statistically significant correlations 
between the summary components (PCS and MCS) and 
the scores obtained from the majority of the subscales.
For sociodemographic and clinical factors, a using t-
independent test, age, marital status, occupational status, 
exercise status, BMI, history of drug abuse, history of dia-
betes, and history of hypertension (Table 3) were related 
to some subscales of HRQOL (p < 0.2). MetS was related 
to more subscales of HRQOL. Gender and passive smok-
er were not related to any subscales in the univariate anal-
ysis (p ≥ 0.2).
In the multivariable analysis, MetS was significantly 
related to four subscales of HRQOL including: RP (B = 
–14.05, p = 0.004), BP (B = –7.37, p = 0.02), VT (B = –7.72, 
p = 0.022) and RE (B: –12.67, p = 0.005) after adjustment 
for other variables. Borderline relationships were ob-
served in the general health and MH subscales and the 
PCS. A borderline relationship was also observed be-
tween exercise activity and the MH subscale (B = –4.70, 
p = 0.087), between occupational status and the RP sub-
scale (B = –8.38, p = 0.083), and between exercise status 
and the physical functioning subscale (B = 7.73, p = 
0.099). A borderline relationship was observed between 
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Fig. 1. Subscales and components of health-
related quality of life (HRQOL) in the study 
population. PF, physical functioning; RP, 
role limitations due to physical problems; 
BP, bodily pain; GH, general health; VT, vi-
tality; SF, social functioning; RE, role limi-
tations due to emotional problems; MH, 
mental health; PCS, Physical Component 
Summary; MCS, Mental Component Sum-
mary.
Table 2. Correlation coefficients for the PCS, the MCS and the 8 subscales of the SF-12
PF RP BP GH VT SF RE MH MCS PCS
PF 1 0.661** 0.553** –0.287** –0.429** –0.348** 0.465** –0.410** –0.229** 0.833**
RP 1 0.438** –0.226** –0.391** –0.324** 0.534** –0.425** –0.152* 0.822**
BP 1 –0.521** –0.397** –0.410** 0.350** –0.440** –0.345** 0.605**
GH 1 0.341** 0.135* –0.169* 0.291** 0.262** –0.025
VT 1 0.358** –0.390** 0.556** 0.674** –0.371**
SF 1 –0.415** 0.463** 0.570** –0.401**
RE 1 –0.562** 0.085 0.514**
MH 1 0.538** –0.429**
MCS 1 –0.198**
PCS 1
PF, physical functioning; RP, role limitations due to physical problems; BP, bodily pain; GF, general health; VT, vitality; SF, social 
functioning; RE, role limitations due to emotional problems; MH, mental health; PCS, Physical Component Summery; MCS, Mental 
Component Summary; SF-12, 12-Item Short-Form Health Survey. * Correlation is significant at the <0.05 level (2-tailed). ** Correlation 
is significant at the <0.001 level (2-tailed). 
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Table 3. Mean scores of the different subscales of HRQOL in the study population
Variable PF RP BP GH VT SF RE MH PCS MCS
Sex
Male 71.4±37.1 67.2±43.2 77.4±28.1 71.4±25.7 43±31.3 20.9±25.3 72.6±42.8 35.3±22.3 71.8±21.2 43±12.6
Female 71.1±36.9 70.8±40.2 78.6±27.4 74.5±25.9 39.4±28.8 20.8±26.3 75.5±41 32.5±19.6 73.7±20.1 42±11.8
p value 0.95 0.47 0.72 0.32 0.30 0.96 0.56 0.26 0.45 0.53
Age
≤42 years 71.3±37.7 69.4±42.1 78.7±29.1 70.3±26.5 41.2±29.9 21.4±26.7 73.4±41.3 34.6±22.1 72.4±22.1 42.7±12
>42 years 71.3±36.3 67.1±42.5 76.9±26.6 74.1±25 42.7±31.3 20.4±24.5 73.5±40.4 34.3±21.1 72.3±19.7 42.7±12.8
p value 0.99 0.60 0.56 0.18* 0.66 0.72 0.98 0.90 0.96 0.96
Education level
Diploma (academic) 69.7±37.7 63.6±44.2 76.8±27.1 73.8±24.6 41.7±30.9 21.4±26.1 70.1±42.8 35.6±25.8 71±21.1 42.2±11.9
No diploma 73.1±36.1 73.4±39.5 78.8±28.7 70.5±27 42.3±30.3 20.3±25 77.2±38.2 33.1±21.3 73.9±20.5 43.2±12.9
p value 0.41 0.03* 0.51 0.24 0.86 0.7 0.11* 0.29 0.20 0.46
Marital status
Married 70.4±37.1 66.8±42.4 77.4±27.7 73.1±25.5 42.4±30.9 21.5±25.7 72.4±41.2 34.8±21.7 72±20.6 43±12.3
Single 77.2±35.7 77.2±41 80.1±28.8 66.5±27 39±28.9 17±24.5 80.6±38.6 32±20.9 75.2±22 42.2±13.1
p value 0.25 0.13* 0.55 0.11* 0.50 0.28 0.18* 0.42 0.32 0.77
Occupational status*
Active 72.9±36.1 71.7±39.7 80±26.6 71±21.6 40.1±29.5 20.7±27.8 75±40.8 32.7±20.8 73.8±20.2 42.1±11.6
Retired 71±37.6 65.5±43.9 72.1±27.6 72±25.8 42.7±31.9 21±26.2 72.6±40.9 35.4±22.5 71.6±21.2 42.9±12.9
p value 0.65 0.196* 0.55 0.71 0.46 0.96 0.61 0.27 0.35 0.59
Obesity
No 78.3±35.1 56.6±45.7 80±30 66.6±24.3 40±26.1 31.6±33.3 86.6±29.6 27.3±21.5 70.4±22.7 46.4±12.2
Yes 70.9±37 68.7±42.1 77.6±27.6 72.5±25.8 42±30.8 20.4±25.1 72.8±41.2 34.8±21.6 72.5±20.8 42.5±12.4
p value 0.64 0.19 0.55 0.71 0.46 0.96 0.60 0.26 0.35 0.58
Exercise status
No 69.3±37.8 67.8±42 77.1±27.5 71.4±26.1 42.2±30.5 21.4±25.7 71.4±41.7 35.8±21.8 71.4±20.8 42.7±12.2
Yes 77.1±33.6 69.2±43.3 79.8±28.8 75±24.7 41.2±30.9 19.2±25 79.5±37.4 30.4±20.6 75.3±20.9 42.6±12
p value 0.08* 0.79 0.44 0.26 0.78 0.50 0.10* 0.05* 0.14* 0.93
History of smoking
No 71.5±35.6 68.9±42.3 77.4±27.8 72.5±25.1 42±30.8 20.6±25.5 74.1±40.8 34±21.6 72.5±20.7 42.6±12.6
Yes 70.2±38.9 64.4±42.3 79.8±27.6 71.1±29 41.9±29.7 22.6±25.8 70.1±41.1 36.9±21.3 71.3±21.7 42.9±11.2
p value 0.81 0.48 0.57 0.75 0.98 0.61 0.52 0.37 0.70 0.90
Passive smoker
No 69.9±36.9 68.1±42.4 77.1±28 72.2±25.2 42.7±31 21.4±26.2 73.8±40.6 34.6±21.9 71.8±20.6 43.1±12.6
Yes 74.2±36.9 68.4±42.1 79.2±27.4 72.4±26.9 40.3±29.8 19.8±24.3 72.6±41.4 34.1±20.9 73.5±21.4 41.7±11.8
p value 0.31 0.95 0.51 0.95 0.51 0.58 0.79 0.84 0.48 0.32
History of drug abuse
No 71.2±37.3 67.5±42.9 78.6±29.2 70.7±26 41.4±31.5 20.9±26.2 74.3±40.1 34.3±22.1 72±21.7 42.8±12.9
Yes 71.4±36.4 69.2±41.3 76.3±25.4 74.8±25.2 42.8±29.1 20.8±24.5 72±42 34.6±20.8 72.9±19.4 42.5±11.5
p value 0.95 0.71 0.45 0.16* 0.69 0.97 0.61 0.91 0.69 0.88
History of alcohol drinking
No 71.3±37 68±42.4 77.7±27.9 72.6±25.4 41.2±30.8 21.4±25.9 72.6±41.5 34.5±21.9 72.4±21.2 42.4±12.3 
Yes 70.8±37 69.4±28.7 77.7±27.2 69.4±28.7 47.7±28.7 16.6±22.3 80.5±34.3 33.6±19.4 71.8±17.7 44.6±13
p value 0.93 0.85 0.99 0.48 0.23 0.29 0.20 0.79 0.87 0.32
History of diabetes
No 71.2±36.9 68±42.5 77.3±28.7 72.7±25.6 42.1±30.5 21.1±25.9 74.5±40.2 34.7±21.8 72.3±21.1 43.1±12.6 
Yes 71.7±37.6 69.2±40.7 80.7±20.2 69.2±26.5 40.5±31.6 19.2±23.2 65.3±44.6 32.3±19.9 72.7±18.6 39.3±10
p value 0.93 0.87 0.35 0.43 0.74 0.65 0.22 0.050* 0.91 0.07*
History of hypertension
No 70±37.3 67.6±42.3 77.2±27.4 71.3±25.9 40±31.7 21.4±25.8 71.9±41.3 34.5±21.9 71.5±20.7 41.9±12.5
Yes 74.4±36 69.5±42.4 79.1±29 74.4±25.2 46.8±27.3 19.5±25 77.3±39.5 34.4±20.9 74.4±21.1 44.5±11.8
p value 0.31 0.70 0.57 0.32 0.06* 0.53 0.27 0.97 0.25 0.08*
Metabolic syndrome
No 73.9±35.6 72±40.77 80.9±25.4 70.2±26.9 46.3±30.5 19.5±25.5 78.9±39.6 32.3±20.7 74.3±20 42.3 ±12.3
Yes 67.5±38.5 63.1±43.8 73.6±30.2 75±24 38.6±30.3 22.7±25.5 66.3±43.7 37.2±22.4 69.9±21.6 43.1±12.4
p value 0.14* 0.06* 0.017* 0.08* 0.02* 0.26 0.006* 0.03* 0.061* 0.55
HRQOL, health-related quality of life; PF, physical functioning; RP, role limitations due to physical problems; BP, bodily pain; GF, general health; VT, vitality; SF, social function-
ing; RE, role limitations due to emotional problems; MH, mental health; PCS, Physical Component Summary; MCS, Mental Component Summary. * Significant at p < 0.2.
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diabetes (B = –3.86, p = 0.067) and hypertension (B = 2.59, 
p = 0.083) in relation to the MCS. Age, education level, 
marital status, obesity, and drug use did not have any re-
lationship with the HRQOL subscales or the summary 
components (p > 0.05) (Table 4).
Discussion
In the present study, the mean BP and SF scores were 
highest and lowest among the SF-12 subscales. Thus, in 
approximately 23% of the participants, the mean BP sub-
scale score implied that pain interfered with their normal 
work and the mean SF subscale score implied that ap-
proximately 79% of the participants had a problem en-
gaging in social interactions, interpersonal relationships, 
and activities of independent living. Moreover, the mean 
MCS score was lower than the mean PCS score. There-
fore, we can conclude that mental health problems were 
more important than physical problems. Furthermore, 
our finding regarding MCS and PCS did not concur with 
studies by Sayiner et al. [18], David et al. [19], and Afendy 
et al. [20]. Our study indicates impairment of HRQOL 
among patients with suspected NASH that is comparable 
with previous reports [21, 22]. In their studies, Golabi et 
al. [23] and Sarrafzadegan et al. [24] illustrated a notice-
able QOL impairment in NAFLD [23, 24].
MetS is a chronic and progressive condition that influ-
ences different aspects of the personal health status such 
as physical, mental, and even sexual functions [25, 26]. 
The prevalence of MetS in countries such as Iran has been 
increasing in recent years [27]. As a result, it may have an 
impact on mental and physical statuses and, eventually, 
QOL. Despite the many studies on MetS, studies regard-
ing MetS and QOL are limited, particularly among pa-
tients with NAFLD/NASH. In the present study, we 
showed that MetS is significantly associated with de-
creased RP, BP, VT, and RE subscale scores after adjust-
ing for other study variables. It also had a borderline as-
sociation with general health, MH, and the PCS. Sarrafza-
degan et al. [24], in a population-based study, observed a 
significant difference between the physical health domain 
of HRQOL in women with and those without MetS [24].
The effect of MetS on the health consequences of pa-
tients with NAFLD/NASH is an understudied determi-
nant of health situations, but enhancing the awareness of 
the medical community about the harmful prevalence of 
MetS among patients with NAFLD/NASH is essential. 
More detailed studies are needed to promote our knowl-
edge on the relationship between MetS and the HRQOL 
of patients with NAFLD/NASH to develop programs for 
improving HRQOL among these patients. In addition, 
previous studies have revealed that visceral fat as a risk 
factor for developing insulin resistance has a great influ-
Table 4. Multivariable analysis of independent variables in relation to 8 dimensions and 2 summary components of HRQOL
Independent variables QOL subscale
PF RP BP GH VT SF RE MH PCS MCS
Sex (female) – – – – – – – – – –
Age (>42 years) – – – 0.68 – – – – – –
Educational level (no diploma) – 0.24 – – – – 0.44 – – –
Marital status (single) – 0.17 – 0.12 – – 0.25 – – –
Occupational status (retired) – 0.083* – – – – – – – –
Obesity (yes) – 0.21 – – – – – – – –
Exercise status (yes) 0.099* – – – – – 0.22 0.076* 0.22 –
History of smoking (yes) – – – – – – – – – –
Passive smoker (yes) – – – – – – – – – –
History of drug abuse (yes) – – – 0.33 – – – – – –
History of alcohol drinking (yes) – – – – – – – – – –
History of diabetes (yes) – – – – – – – 0.19 – 0.067*
History of hypertension (yes) – – – – 0.155 – – – – 0.083*
Metabolic syndrome (yes) 0.2 0.004** 0.017** 0.094* 0.022** – 0.005** 0.065* 0.058* –
HRQOL, health-related quality of life; PF, physical functioning; RP, role limitations due to physical problems; BP, bodily pain; GF, 
general health; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health; PCS, Physical 
Component Summery; MCS, Mental Component Summery. * Significant at p < 0.1. ** Significant at p < 0.05. 
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ence on the development of Mets and NAFLD. Therefore, 
as a result, the reduction of visceral fat may influence the 
improvement of MetS and its adverse effects, such as 
NAFLD and cardiovascular disease [28, 29].
The limitations of this study include its cross-section-
al nature and not using factors, such as local residence 
and ethnicity, that might have impacted the results. The 
SF-12 is a self-reported HRQOL instrument that might be 
affected by factors that are not related to MetS.
Conclusion
In this study, patients with suspected NASH showed a 
relatively strong association between MetS and the scores 
on 4 subscales (RP, BP, VT, and RE) of HRQOL, which 
could consequently play a role in advancing the disease. 
Therefore, HRQOL might play an important role in the 
development of NAFLD/NASH.
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